{
    "nct_id": "NCT02989402",
    "title": "A Prospective, 16 Week, Phase IV Study to Evaluate Safety, Tolerability and Effectiveness in Patients With Severe Dementia of the Alzheimer's Type Exposed to Rivastigmine (Exelon)15cm2 Transdermal Patch",
    "status": "COMPLETED",
    "last_update_time": "2023-12-08",
    "description_brief": "This was a multicenter, prospective, phase IV study evaluating safety, tolerability and effectiveness of rivastigmine 27 mg -15 cm\\^2 transdermal patch prescribed in patients with severe dementia of the Alzheimer's type as per discretion of treating physician.",
    "description_detailed": "This was a multicenter, prospective, single-arm, open-label, phase IV study to evaluate safety, tolerability and effectiveness of Rivastigmine 27 mg -15 cm\\^2 transdermal patch prescribed in patients with severe dementia of the Alzheimer's type as per discretion of treating physician. Male and female patients who were treated according to local routine clinical practice were enrolled in the study upon signing informed consent. The prescription decision was independent of the decision for inclusion in the study.",
    "phase": [
        "PHASE4"
    ],
    "study_type": "INTERVENTIONAL",
    "primary_purpose": "TREATMENT",
    "results": {
        "participantFlowModule": {
            "preAssignmentDetails": "Participants who were treated according to local routine clinical practice were enrolled in the study upon signing informed consent.",
            "recruitmentDetails": "Participants took part in 9 investigative sites in India.",
            "groups": [
                {
                    "id": "FG000",
                    "title": "Rivastigmine Patch",
                    "description": "15 cm\\^2 patch sizes loaded with 27 mg of rivastigmine - one patch per day"
                }
            ],
            "periods": [
                {
                    "title": "Overall Study",
                    "milestones": [
                        {
                            "type": "STARTED",
                            "achievements": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "100"
                                }
                            ]
                        },
                        {
                            "type": "COMPLETED",
                            "achievements": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "72"
                                }
                            ]
                        },
                        {
                            "type": "NOT COMPLETED",
                            "achievements": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "28"
                                }
                            ]
                        }
                    ],
                    "dropWithdraws": [
                        {
                            "type": "Adverse event, or serious adverse event",
                            "reasons": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "4"
                                }
                            ]
                        },
                        {
                            "type": "Death",
                            "reasons": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "2"
                                }
                            ]
                        },
                        {
                            "type": "Discontinuation of study treatment and premature patient withdrawal",
                            "reasons": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "3"
                                }
                            ]
                        },
                        {
                            "type": "Lost to Follow-up",
                            "reasons": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "8"
                                }
                            ]
                        },
                        {
                            "type": "Patient no longer on monotherapy",
                            "reasons": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "1"
                                }
                            ]
                        },
                        {
                            "type": "Patient stopped Exelon\u00ae patch treatment",
                            "reasons": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "1"
                                }
                            ]
                        },
                        {
                            "type": "Withdrawal by Subject",
                            "reasons": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "7"
                                }
                            ]
                        },
                        {
                            "type": "Other",
                            "reasons": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "2"
                                }
                            ]
                        }
                    ]
                }
            ]
        },
        "baselineCharacteristicsModule": {
            "groups": [
                {
                    "id": "BG000",
                    "title": "Rivastigmine Patch",
                    "description": "15 cm\\^2 patch sizes loaded with 27 mg of rivastigmine - one patch per day"
                }
            ],
            "denoms": [
                {
                    "units": "Participants",
                    "counts": [
                        {
                            "groupId": "BG000",
                            "value": "100"
                        }
                    ]
                }
            ],
            "measures": [
                {
                    "title": "Age, Continuous",
                    "paramType": "MEAN",
                    "dispersionType": "STANDARD_DEVIATION",
                    "unitOfMeasure": "years",
                    "classes": [
                        {
                            "denoms": [
                                {
                                    "units": "Participants",
                                    "counts": [
                                        {
                                            "groupId": "BG000",
                                            "value": "100"
                                        }
                                    ]
                                }
                            ],
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "72.3",
                                            "spread": "9.05"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "title": "Sex: Female, Male",
                    "paramType": "COUNT_OF_PARTICIPANTS",
                    "unitOfMeasure": "Participants",
                    "classes": [
                        {
                            "denoms": [
                                {
                                    "units": "Participants",
                                    "counts": [
                                        {
                                            "groupId": "BG000",
                                            "value": "100"
                                        }
                                    ]
                                }
                            ],
                            "categories": [
                                {
                                    "title": "Female",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "51"
                                        }
                                    ]
                                },
                                {
                                    "title": "Male",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "49"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "title": "Race and Ethnicity Not Collected",
                    "populationDescription": "Race and Ethnicity were not collected from any participant.",
                    "paramType": "COUNT_OF_PARTICIPANTS",
                    "unitOfMeasure": "Participants",
                    "classes": [
                        {
                            "denoms": [
                                {
                                    "units": "Participants",
                                    "counts": [
                                        {
                                            "groupId": "BG000",
                                            "value": "0"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                }
            ]
        },
        "outcomeMeasuresModule": {
            "outcomeMeasures": [
                {
                    "type": "PRIMARY",
                    "title": "Number of Participants With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)",
                    "description": "Number of participants with treatment emergent AEs (any AE regardless of seriousness), AEs related to study treatment, AEs led to study treatment discontinuation, and SAEs.",
                    "populationDescription": "The safety set included all patients who provided informed consent to collect information and who were treated with at least one patch of Rivastigmine 27 mg -15 cm2 transdermal patch during this study.",
                    "reportingStatus": "POSTED",
                    "paramType": "COUNT_OF_PARTICIPANTS",
                    "unitOfMeasure": "Participants",
                    "timeFrame": "Adverse events were reported from first dose of study treatment until end of study treatment, plus 30 days post treatment, up to a maximum duration of approximately 142 days.",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Rivastigmine Patch",
                            "description": "15 cm\\^2 patch sizes loaded with 27 mg of rivastigmine - one patch per day"
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "100"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "title": "At least one AE",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "32"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "AEs related to study treatment",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "13"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "AEs leading to treatment discontinuation",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "4"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "At least one SAE",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "4"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "type": "SECONDARY",
                    "title": "Change From Baseline in Mini-Mental State Examination (MMSE)",
                    "description": "The MMSE is a brief, practical screening test for cognitive dysfunction. The test consists of five sections (orientation, registration, attention-calculation, recall, and language); and results in a total score can range from 0 to 30, with higher scores indicating better function.",
                    "populationDescription": "Patients in the intend to treat (ITT) set who had a valid assessment of the outcome measure at week 16. The intend to treat (ITT) set included all patients who signed the informed consent and who had at least one post-baseline assessment.",
                    "reportingStatus": "POSTED",
                    "paramType": "MEAN",
                    "dispersionType": "Standard Deviation",
                    "unitOfMeasure": "Score on a scale",
                    "timeFrame": "Baseline, 16 weeks",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Rivastigmine Patch",
                            "description": "15 cm\\^2 patch sizes loaded with 27 mg of rivastigmine - one patch per day"
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "63"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "3.1",
                                            "spread": "4.79"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "type": "SECONDARY",
                    "title": "Change From Baseline in Alzheimer's Disease Cooperative Study - Activities of Daily Living Inventory - Severe Impairment Version (ADCS-ADL SIV) Score",
                    "description": "Alzheimer's Disease Cooperative Study - Activities of Daily Living Inventory - Severe Impairment Version (ADCS-ADL SIV) score is a tool to assess the ability of patients with moderate to severe dementia to perform activities of daily living. The ADCS-ADL SIV assessment is done at start and end of visit. The assessment includes 19 questions. The total score ranges from 0 - 54. Higher scores indicate less functional impairment and greater competence.",
                    "populationDescription": "Patients in the intend to treat (ITT) set who had a valid assessment of the outcome measure at week 16. The intend to treat (ITT) set included all patients who signed the informed consent and who had at least one post-baseline assessment.",
                    "reportingStatus": "POSTED",
                    "paramType": "MEAN",
                    "dispersionType": "Standard Deviation",
                    "unitOfMeasure": "Score on a scale",
                    "timeFrame": "Baseline, 16 weeks",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Rivastigmine Patch",
                            "description": "15 cm\\^2 patch sizes loaded with 27 mg of rivastigmine - one patch per day"
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "69"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "-1.6",
                                            "spread": "10.47"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "type": "SECONDARY",
                    "title": "Compliance by Caregiver Medication Questionnaire (CMQ) Score",
                    "description": "Caregiver evaluation of the medications used for Alzheimer Disease was assessed using the Caregiver Medication Questionnaire (CMQ). Compliance was rated on a scale from 0 = \"never took the medication as prescribed\" to 10 = \"always took the medication as prescribed.\"",
                    "populationDescription": "Patients in the intend to treat (ITT) set who had a valid assessment of the outcome measure at week 16. The intend to treat (ITT) set included all patients who signed the informed consent and who had at least one post-baseline assessment.",
                    "reportingStatus": "POSTED",
                    "paramType": "MEAN",
                    "dispersionType": "Standard Deviation",
                    "unitOfMeasure": "Score on a scale",
                    "timeFrame": "Week 16",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Rivastigmine Patch",
                            "description": "15 cm\\^2 patch sizes loaded with 27 mg of rivastigmine - one patch per day"
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "69"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "8.1",
                                            "spread": "2.78"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "type": "SECONDARY",
                    "title": "Number of Participants With a Skin Irritation",
                    "description": "The following score system were used to assess skin irritation:\n\nI. Dermal response:\n\nScore 0 = No erythema (normal skin) Score 1 = Erythema barely visible Score 2 = Mild erythema Score 3 = Moderate erythema Score 4 = Severe erythema Score 5 = Severe erythema with vesicles or blisters",
                    "populationDescription": "Patients in the safety set who had a dermal response score at week 16. The safety set included all patients who provided informed consent to collect information and who were treated with at least one patch of Rivastigmine 27 mg -15 cm2 transdermal patch during this study.",
                    "reportingStatus": "POSTED",
                    "paramType": "NUMBER",
                    "unitOfMeasure": "participants",
                    "timeFrame": "Week 16",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Rivastigmine Patch",
                            "description": "15 cm\\^2 patch sizes loaded with 27 mg of rivastigmine - one patch per day"
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "70"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "title": "Score 0",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "65"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "Score 1",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "3"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "Score 2",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "2"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "Score 3 to 5",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "0"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "type": "SECONDARY",
                    "title": "Number of Participants With a Urinary Tract Infection (UTI)",
                    "description": "Urine samples were collected to assess the number of patients with UTI.",
                    "populationDescription": "The safety set included all patients who provided informed consent to collect information and who were treated with at least one patch of Rivastigmine 27 mg -15 cm2 transdermal patch during this study.",
                    "reportingStatus": "POSTED",
                    "paramType": "COUNT_OF_PARTICIPANTS",
                    "unitOfMeasure": "Participants",
                    "timeFrame": "16 weeks",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Rivastigmine Patch",
                            "description": "15 cm\\^2 patch sizes loaded with 27 mg of rivastigmine - one patch per day"
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "100"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "10"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "type": "SECONDARY",
                    "title": "Patch Adhesion to the Skin",
                    "description": "Patch adhesion to the skin was evaluated by the caregiver. An estimate of the patch adherence was provided and graded according to the patch adhesiveness score.\n\nFollowing scores were used to capture comments relating to patch adhesion:\n\n0 = 90 % adhered (essentially no lift off of the skin)\n\n1. = 75% to \\< 90% adhered (some edges only lifting off of the skin)\n2. = 50% to \\< 75% adhered (less than half of the patch lifting off the skin)\n3. = \\< 50% adhered but not detached (more than half the system lifting off of the skin without falling off)\n4. = the patch was completely detached. The score ranges from 1 to 4 where a higher score indicates less adhesion.",
                    "populationDescription": "Patients in the safety set who had a dermal response score at week 16. The safety set included all patients who provided informed consent to collect information and who were treated with at least one patch of Rivastigmine 27 mg -15 cm2 transdermal patch during this study.",
                    "reportingStatus": "POSTED",
                    "paramType": "NUMBER",
                    "unitOfMeasure": "participants",
                    "timeFrame": "Week 16",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Rivastigmine Patch",
                            "description": "15 cm\\^2 patch sizes loaded with 27 mg of rivastigmine - one patch per day"
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "70"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "title": "Score 0",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "60"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "Score 1",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "4"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "Score 2",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "0"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "Score 3",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "4"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "Score 4",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "2"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                }
            ]
        },
        "adverseEventsModule": {
            "frequencyThreshold": "2",
            "timeFrame": "Adverse events were reported from first dose of study treatment until end of study treatment, plus 30 days post treatment, up to a maximum duration of approximately 142 days.",
            "eventGroups": [
                {
                    "id": "EG000",
                    "title": "Rivastigmine Patch",
                    "description": "15 cm\\^2 patch sizes loaded with 27 mg of rivastigmine - one patch per day",
                    "deathsNumAffected": 2,
                    "deathsNumAtRisk": 100,
                    "seriousNumAffected": 4,
                    "seriousNumAtRisk": 100,
                    "otherNumAffected": 16,
                    "otherNumAtRisk": 100
                }
            ],
            "seriousEvents": [
                {
                    "term": "ARRHYTHMIA",
                    "organSystem": "Cardiac disorders",
                    "sourceVocabulary": "MedDRA (20.1)",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 100
                        }
                    ]
                },
                {
                    "term": "RESPIRATORY TRACT INFECTION",
                    "organSystem": "Infections and infestations",
                    "sourceVocabulary": "MedDRA (20.1)",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 100
                        }
                    ]
                },
                {
                    "term": "CEREBRAL HAEMORRHAGE",
                    "organSystem": "Nervous system disorders",
                    "sourceVocabulary": "MedDRA (20.1)",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 100
                        }
                    ]
                },
                {
                    "term": "CEREBROSPINAL FLUID LEAKAGE",
                    "organSystem": "Nervous system disorders",
                    "sourceVocabulary": "MedDRA (20.1)",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 100
                        }
                    ]
                },
                {
                    "term": "DEMENTIA",
                    "organSystem": "Nervous system disorders",
                    "sourceVocabulary": "MedDRA (20.1)",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 100
                        }
                    ]
                },
                {
                    "term": "HYPONATRAEMIC SEIZURE",
                    "organSystem": "Nervous system disorders",
                    "sourceVocabulary": "MedDRA (20.1)",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 100
                        }
                    ]
                },
                {
                    "term": "PNEUMONIA ASPIRATION",
                    "organSystem": "Respiratory, thoracic and mediastinal disorders",
                    "sourceVocabulary": "MedDRA (20.1)",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 100
                        }
                    ]
                }
            ],
            "otherEvents": [
                {
                    "term": "VOMITING",
                    "organSystem": "Gastrointestinal disorders",
                    "sourceVocabulary": "MedDRA (20.1)",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 3,
                            "numAtRisk": 100
                        }
                    ]
                },
                {
                    "term": "URINARY TRACT INFECTION",
                    "organSystem": "Infections and infestations",
                    "sourceVocabulary": "MedDRA (20.1)",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 10,
                            "numAtRisk": 100
                        }
                    ]
                },
                {
                    "term": "DECREASED APPETITE",
                    "organSystem": "Metabolism and nutrition disorders",
                    "sourceVocabulary": "MedDRA (20.1)",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 3,
                            "numAtRisk": 100
                        }
                    ]
                },
                {
                    "term": "SKIN IRRITATION",
                    "organSystem": "Skin and subcutaneous tissue disorders",
                    "sourceVocabulary": "MedDRA (20.1)",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 3,
                            "numAtRisk": 100
                        }
                    ]
                }
            ]
        },
        "moreInfoModule": {
            "certainAgreement": {
                "piSponsorEmployee": false,
                "restrictionType": "OTHER",
                "restrictiveAgreement": true,
                "otherDetails": "The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial."
            },
            "pointOfContact": {
                "title": "Study Director",
                "organization": "Novartis Pharmaceuticals",
                "email": "novartis.email@novartis.com",
                "phone": "+ 1 862 778 8300"
            }
        }
    },
    "target_category": "cognitive enhancer",
    "drug": [
        "rivastigmine (Exelon) 27 mg / 15 cm^2 transdermal patch \u2014 rivastigmine tartrate, a cholinesterase inhibitor"
    ],
    "placebo": [],
    "explanation_target": [
        "Reason: The intervention is rivastigmine delivered via a transdermal patch (Exelon). Rivastigmine is a reversible cholinesterase inhibitor that increases acetylcholine to improve cholinergic neurotransmission \u2014 a symptomatic (cognitive) treatment approach rather than a disease-modifying one. \ue200cite\ue202turn0search1\ue202turn0search6\ue201.",
        "Act: Key trial details extracted from the description \u2014 drug: rivastigmine (Exelon) transdermal patch, 27 mg (15 cm^2) used in patients with severe Alzheimer\u2019s-type dementia. The patch formulation is approved and used to treat Alzheimer\u2019s dementia and has been studied specifically in severe AD and in higher-dose patch formulations. \ue200cite\ue202turn0search4\ue202turn0search8\ue201.",
        "Reflect: Classification check \u2014 rivastigmine\u2019s mechanism and clinical use are consistent with the 'Cognitive enhancer' category (symptomatic improvement of cognition and global function, not targeting amyloid/tau pathology for disease modification). Systematic reviews and clinical trials report small cognitive and functional benefits with rivastigmine patches vs placebo, supporting symptomatic cognitive enhancement. No evidence in the trial description indicates an anti-amyloid/tau biologic or a primary neuropsychiatric-targeted intervention, so 'cognitive enhancer' is the best fit. \ue200cite\ue202turn0search2\ue202turn0search5\ue201."
    ],
    "agent_type": "D) Neurotransmitter Receptors",
    "explanation_agent": [
        "Reason: The trial tests rivastigmine (Exelon) delivered by transdermal patch. Rivastigmine is a cholinesterase inhibitor that increases synaptic acetylcholine and thus augments cholinergic neurotransmission to produce symptomatic (cognitive) benefit rather than directly modifying amyloid/tau pathology. \ue200cite\ue202turn0search7\ue202turn0search1\ue201",
        "Act: Key extracted details \u2014 drug: rivastigmine (Exelon) transdermal patch (15 cm\u00b2 formulation corresponds to the higher\u2011dose/13.3 mg/24 h patch, containing 27 mg rivastigmine base in the 15 cm\u00b2 system); indication and clinical use include treatment of mild-to-severe Alzheimer\u2019s-type dementia and symptomatic cognitive improvement has been demonstrated in clinical trials of the patch. \ue200cite\ue202turn1search7\ue202turn1search0\ue202turn0search5\ue201",
        "Reflect: Classification check \u2014 the intervention modulates neurotransmitter signaling (cholinergic system) via inhibition of acetylcholinesterase/butyrylcholinesterase and is a symptomatic cognitive enhancer. Under CADRO, interventions that act on neurotransmitter systems (cholinergic modulation) are best captured by D) Neurotransmitter Receptors (neurotransmitter system modulation). There is no indication in the description that the trial targets amyloid, tau, inflammation, synaptic repair as a disease\u2011modifying strategy, nor that multiple distinct pathological pathways are being targeted, so 'D) Neurotransmitter Receptors' is the most specific CADRO category. \ue200cite\ue202turn0search7\ue202turn0search3\ue201",
        "Sources used (web search results cited above):",
        "- Rivastigmine mechanism and cholinesterase inhibition (StatPearls / NCBI). \ue200cite\ue202turn0search7\ue201",
        "- Rivastigmine reviews describing mechanism and symptomatic use. \ue200cite\ue202turn0search1\ue201",
        "- Novartis / Exelon Patch prescribing and approval information (indications, patch dosing). \ue200cite\ue202turn1search0\ue202turn1search1\ue201",
        "- Clinical trials and analyses of higher\u2011dose rivastigmine patch (OPTIMA, ACTION, dose comparison studies supporting use in severe AD). \ue200cite\ue202turn0search5\ue202turn0search8\ue202turn0search10\ue201"
    ]
}